Mark A. Velleca, Director at G1 Therapeutics, Inc. (GTHX), sold 60,000 shares at $2.00 ($120K) on 2023-08-08, disclosed to the SEC on 2023-08-10.
Scheduled sale ($120k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.00 | 57,286 | $115K | 95.4% |
| 2 | $2.02 | 2,714 | $5K | 4.6% |
| Total | $2.00 avg | 60,000 | $120K | 100% |
| Filing → |
| GTHX | SELL | 2022-08-18 | $1.0M | — | Filing → |
| GTHX | SELL | 2021-07-15 | $946K | — | Filing → |
| GTHX | SELL | 2021-06-17 | $876K | — | Filing → |